CLPT at a glance
ClearPoint Neuro, Inc. (CLPT, SEC CIK 1285550) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ClearPoint Neuro, Inc. (CLPT) reported revenue of $37.0 million (up 17.8% from FY2024) and a net loss of $25.5 million. Diluted EPS was -$0.90.
- As of June 30, 2026, 21 institutional investment managers tracked by SignalX reported holding ClearPoint Neuro, Inc. (CLPT) shares worth $108.9 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $37.0M
- +17.8% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 21 funds
- $108.9M · +1 vs prior quarter
- Latest 8-K
- Aug 3, 2026
- Item 7.01 · Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New CAL facility risk triggered by preclinical CRO expansion and significant capital investment
- Most material update: CAL build-out and commissioning exposed to construction delays, cost overruns, equipment constraints, and vendor failures
- Compliance risk: inability to achieve or maintain GLP standards could prevent GLP studies and delay revenue
- Near-term operating risk: insufficient customer demand or delayed statements of work could leave CAL capacity underutilized
- Financial risk: fixed and variable CAL costs may exceed facility revenue, preventing an adequate investment return
AI summary of the CLPT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Updated investor presentation furnished under Regulation FD, creating a reference point for investor and analyst communications
- Presentation available on ClearPoint Neuro’s investor-relations website and filed as Exhibit 99.2
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the company’s financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue $10.9M, up 18% YoY, driven by neurosurgery navigation and therapy revenue growth of 62% to $5.6M
- Biologics and drug delivery revenue fell 15% to $4.0M, reflecting lower biopharma trial-related product shipments
Item 5.07: Submission of Matters to a Vote of Security Holders
- Seven director nominees elected to serve through 2027, preserving board continuity
- Cherry Bekaert LLP auditor appointment ratified for fiscal 2026 with 19,296,330 votes for
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stockholders approved the Seventh Amended and Restated 2013 Incentive Compensation Plan, enabling continued equity-based compensation
- Audit Committee chaired by Lynnette C. Fallon, with R. John Fletcher designated audit committee financial expert
Item 2.02: Results of Operations and Financial Condition
- Q1 fiscal 2026 results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains financial figures and management commentary
Item 7.01: Regulation FD Disclosure
- Updated investor presentation furnished as Exhibit 99.2 for analyst and investor discussions
- Presentation available on ClearPoint Neuro’s investor-relations website
AI summaries of CLPT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CLPT
Don't miss the next CLPT filing
- Alerts as it files. A push when CLPT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CLPT, by share count.
- Ask anything. An AI agent that reads every CLPT filing and answers with sources.
CLPT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| FLETCHER R JOHN | A | Oct 1, 2026 | 993 | $12.21 |
| Richards Timothy T. | A | Oct 1, 2026 | 319 | $12.21 |
| BURNETT JOSEPH | M | Sep 2, 2026 | 12,517 | - |
| BURNETT JOSEPH | M | Sep 2, 2026 | 12,517 | $3.47 |
| FLETCHER R JOHN | A | Jul 1, 2026 | 662 | $17.84 |
| Richards Timothy T. | A | Jul 1, 2026 | 222 | $17.84 |
| BURNETT JOSEPH | A | Jun 30, 2026 | 1,361 | $11.93 |
| D'Alessandro Danilo | A | Jun 30, 2026 | 1,085 | $11.93 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $31.4M | $37.0M |
| Gross Profit | - | $19.1M | $22.7M |
| Operating Income | - | -$19.7M | -$24.2M |
| Net Income | - | -$18.9M | -$25.5M |
| Gross Margin | - | 60.9% | 61.4% |
| Op. Margin | - | -62.9% | -65.4% |
| Net Margin | - | -60.3% | -69.1% |
| Balance Sheet | |||
| Total Assets | $42.7M | $39.2M | $97.7M |
| Equity | - | $25.4M | $28.0M |
| ROE | - | -74.5% | -91.1% |
| Per Share | |||
| EPS | - | $-0.70 | $-0.90 |
| Cash Flow | |||
| Operating CF | - | -$8.9M | -$23.9M |
| CapEx | $717K | $275K | $522K |
Source: XBRL data in ClearPoint Neuro, Inc. (CLPT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CLPT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 21 | $108.9M |
| Q1 2026 | 20 | $53.5M |
| Q4 2025 | 22 | $88.0M |
| Q3 2025 | 19 | $119.5M |
| Q2 2025 | 21 | $63.2M |
| Q1 2025 | 14 | $36.9M |
| Q4 2024 | 11 | $37.1M |
| Q3 2024 | 8 | $10.0M |
- BlackRock+297.1K (+14%)
- State Street Corp+136.7K (+20%)
- Millennium Management+125.7K (+54%)
- Morgan Stanley+35.9K (+28%)
- Northern Trust+21.6K (+10%)
- Goldman Sachs Group−324.7K (-70%)
- Vanguard Portfolio Management LLC−90.2K (-32%)
- Two Sigma Investments−55.9K (-27%)
- Vanguard Capital Management LLC−10.8K (-1%)
- Citigroup−7.4K (-36%)
- Citadel Advisors LLC+48.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 136 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CLPT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
CLPT SEC filings: frequently asked questions
Which institutions hold CLPT stock?
As of June 30, 2026, the largest ClearPoint Neuro, Inc. (CLPT) holders among the 13F filers tracked by SignalX were BlackRock ($42.5 million), Vanguard Capital Management LLC ($22.0 million), State Street Corp ($14.6 million), Millennium Management ($6.4 million), Northern Trust ($4.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CLPT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ClearPoint Neuro, Inc. (CLPT) reported revenue of $37.0 million (up 17.8% from FY2024) and a net loss of $25.5 million. Diluted EPS was -$0.90. The figures come from the XBRL data in the 10-K.
What did CLPT report in its latest 8-K?
ClearPoint Neuro, Inc. (CLPT) filed an 8-K on August 3, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Updated investor presentation furnished under Regulation FD, creating a reference point for investor and analyst communications.
What are the latest CLPT SEC filings?
ClearPoint Neuro, Inc. (CLPT) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and a Form 4 insider filing on October 2, 2026.
What is CLPT's SEC CIK number?
ClearPoint Neuro, Inc. (CLPT)'s SEC Central Index Key (CIK) is 1285550. EDGAR lists every CLPT filing under that number.
Ask anything about CLPT
The research agent reads CLPT's filings, financials, insider trades and 13F holders, then answers with sources.